CXCL-14在非小细胞肺癌中的表达水平及临床意义

目的:检测CXC趋化因子配体14(CXCL-14)在非小细胞肺癌（NSCLC）中的表达水平并分析其临床意义。方法:收集2017年1月—2019年1月在郑州人民医院接受手术治疗的NSCLC患者260例。检测NSCLC组织、癌旁组织、NSCLC细胞A549、H1975、PC-9和正常肺上皮细胞BEAS-2B细胞CXCL-14 mRNA的相对表达水平；将siCXCL-141（siCXCL-141组）、siCXCL-142（siCXCL-142组)和si-RNA（对照组）质粒转染至A549细胞中，检测转染后细胞的增殖和凋亡情况；根据CXCL-14的平均表达水平将患者分为CXCL-14高表达组（n=138）与CXCL-14低表达组（n=122），分析各组患者的临床特征。结果:CXCL-14 mRNA在NSCLC组织中的相对表达水平为（3.62±0.78），高于癌旁组织（1.17±0.32），差异有统计学意义（t=22.440，P<0.001）。CXCL-14 mRNA在A549、H1975和PC-9中的相对表达水平分别为（2.10±0.13）、（1.84±0.21）和（1.47±0.08），均高于正常肺上皮细胞（0.69±0.08），差异有统计学意义（q=23.631、17.882、13.568，P<0.001）；siCXCL-141组和siCXCL-142组CXCL-14 mRNA和蛋白相对表达水平均低于对照组，差异有统计学意义（均P<0.05）；72 h时siCXCL-141组和siCXCL-142组细胞的OD值分别为（1.02±0.19）和（0.98±0.12），均低于对照组（1.63±0.21），差异有统计学意义（q=3.102，P=0.015；q=3.241，P=0.012）；siCXCL-141组和siCXCL-142组细胞凋亡率分别为（13.57±2.82）%和（14.41±2.14）%，高于对照组的（5.58±0.69）%，差异有统计学意义（q=4.774，P=0.009；q=7.031，P=0.002）；CXCL-14高表达组低分化、病理分期Ⅱ、Ⅲ期和淋巴结转移的患者多于CXCL-14低表达组，1年无进展生存的患者少于CXCL-14低表达组，差异均有统计学意义（均P<0.05）。结论:CXCL-14在NSCLC中表达增加，降低CXCL-14的表达可减弱细胞的增殖、促进细胞凋亡，CXCL-14表达水平增加可反映患者的不良预后。

The expression level and clinical significance of CXCL-14 in non-small cell lung cancer

Objective: To detect the expression level of CXC chemokine ligand 14（CXCL-14) in non-small cell lung cancer（NSCLC) and analyze its clinical significance. Methods: A total of 260 patients with NSCLC who underwent surgical treatment at People′s Hospital of Zhengzhou from January 2017 to January 2019 were collected.The expression of CXCL-14 mRNA in NSCLC tissues，paracancerous tissues，NSCLC cells A549，h1975，PC-9 and BEAS-2B cells were detected；siCXCL-141（siCXCL-141 group），siCXCL-142（siCXCL-142 group） and si-RNA（control group） plasmids were transfected into A549 cells.The proliferation and apoptosis of transfected cells were detected. According to the average level of CXCL-14 expression，patients were divided into CXCL-14 high expression group and CXCL-14 low expression group，and the clinical characteristics of patients between different groups were analyzed. Results: The relative expression level of CXCL-14 mRNA in NSCLC tissues was（3.62±0.78），higher than that of adjacent tissues（1.17±0.32)]，the difference was statistically significant（t=22.440，P<0.001）.The relative expression levels of CXCL-14 mRNA in A549，H1975 and PC-9 were（2.10±0.13），（1.84±0.21）and（1.47±0.08），respectively，which were higher than that in normal lung epithelial cells（0.69±0.08），and the difference was statistically significant（q=23.631，17.882，13.568，P<0.001）.The relative expression levels of CXCL-14 mRNA and protein in siCXCL-141 group and siCXCL-142 group were lower than those in control group，and the difference was statistically significant （P<0.05）. At 72 h，the OD values of cells in the siCXCL-141 group and siCXCL-142 group were（1.02±0.19） and（0.98±0.12），both of which were lower than those in control group（1.63±0.21），the difference was statistically significant（q=3.102，P=0.015；q=3.241，P=0.012）；the apoptosis rates of siCXCL-141 group and si CXCL-142 group were （13.57±2.82）% and （14.41±2.14）%，which were higher than that of control group（5.58±0.69）%，the difference was statistically significant（q=4.774，P=0.009；q=7.031，P=0.002）；there were more patients with poor differentiation，pathological stage Ⅱ，Ⅲ and lymph node metastasis in the CXCL-14 high expression group than those in the CXCL-14 low expression group. The number of 1-year progression-free survival patients was less than that in the CXCL-14 low expression group，the difference was statistically significant（P<0.05）. Conclusion: The expression of CXCL-14 increases in NSCLC. Decreasing the expression of CXCL-14 can weaken cell proliferation and promote cell apoptosis. Increased expression of CXCL-14 can reflect the poor prognosis of patients，and is expected to become an effective target for the treatment of NSCLC.